The treatment, a twice-yearly lenacapavir injection, is a promising alternative to daily PrEP pills like Truvada, showing 100% efficacy in early trials at the AIDS 2024 conference in Munich.
In a double-blind study of 5,300 women in South Africa and Uganda, those who received lenacapavir injections showed zero HIV infections, while oral PrEP participants had a 2% infection rate, leading to halting the trial for immediate lenacapavir provision.
Collection
[
|
...
]